NCT00205816

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations. The secondary objective is to evaluate the safety and efficacy of tigecycline in the treatment of patients with selected serious infections where other treatment has not been successful.

Conditions

• Bacterial Infections

Interventions

Type	Name	Description
DRUG	Tigecycline

Timeline

• Start date: 2004-01-01
• Primary completion: 2005-11-01
• Completion: 2005-11-01
• First posted: 2005-09-20
• Last updated: 2013-02-08

Locations

3 sites across 2 countries: Germany, Poland